1-8 of 8
Susana Ros
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I. Fisher, Eric T. Gangl, Hilary Lewis, Dawn Trueman, Neha Wali, Stuart C. Williamson, Jennifer Moss, Elodie Montaudon, Heloise Derrien, Elisabetta Marangoni, Ricardo J. Miragaia, Sladjana Gagrica, Pablo Morentin-Gutierrez, Thomas A. Moss, Gareth Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E. Critchlow, James S. Scott, Justin P.O. Lindemann, Simon T. Barry, Teresa Klinowska, Christopher J. Morrow, Larissa S. Carnevalli
Journal: Cancer Research
Cancer Res (2023) 83 (23): 3989–4004.
https://doi.org/10.1158/0008-5472.CAN-23-0694
Published: 01 December 2023
View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Open the PDF for The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors

Larissa Carnevalli, Susana Ros, Jelena Urosevic, Natalie Cureton, Sophie Darcy, Mandy Lawson, Stuart Williamson, Pablo Morentin Gutierrez, Azadeh Bashi, Jennifer Moss, Christopher Morrow, Barry Simon, Teresa Klinowska
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD10-04.
https://doi.org/10.1158/1538-7445.SABCS22-PD10-04
Published: 01 March 2023
View article titled, Abstract PD10-04: PD10-04 Combination of the next generation oral SERD camizestrant (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors
Journal Articles

Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α

Christopher Morrow, Larissa Carnevalli, Richard D. Baird, Tim Brier, Carmela Ciardullo, Natalie Cureton, Mandy Lawson, Robert McEwen, Myria Nikolaou, Anne Armstrong, Begoña Bermejo, Emiliano Calvo, Eva Ciruelos, Javier Garcia-Corbacho, Erika Hamilton, Jason Incorvati, Peter Kabos, Mafalda Oliveira, Manish R Patel, Manuel Ruiz-Borregó, Nicholas Turner, Chris Twelves, Christos Vaklavas, Danielle Carroll, Steven Ching, Nevena Cvetesic, Michelle DuPont, Lisa Gibbons, Alastair Mathewson, Rhiannon Maudsley, Pablo Morentin Gutierrez, Avinash Reddy, Jaime Rodriguez-Canales, Susana Ros, Dhivya Sudhan, Andy Sykes, David Whitson, Teresa Klinowska, Justin Lindemann
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-07-13.
https://doi.org/10.1158/1538-7445.SABCS22-P3-07-13
Published: 01 March 2023
View article titled, Abstract P3-07-13: The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α
Journal Articles

Abstract 2179: Increased BCAT1 expression creates a pseudo-hypoxic environment that promotes cell proliferation in a subtype of glioblastoma

Maria Fala, Susana Ros, Ashley Sawle, Kevin M. Brindle
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2179.
https://doi.org/10.1158/1538-7445.AM2022-2179
Published: 15 June 2022
View article titled, Abstract 2179: Increased BCAT1 expression creates a pseudo-hypoxic environment that promotes cell proliferation in a subtype of glioblastoma
Journal Articles

Abstract 2817: Metabolic heterogeneity in breast cancer integrative clusters to screen metabolic vulnerabilities for diagnosis and treatment response

Susana Ros, Alan J. Wright, Flaviu Bulat, Wendy Greenwood, De-en Hu, Maurizio Callari, Ming Li Chia, Violeta Serra, Oscar Rueda, Alejandra Bruna, Carlos Caldas, Kevin M. Brindle
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2817.
https://doi.org/10.1158/1538-7445.AM2021-2817
Published: 01 July 2021
View article titled, Abstract 2817: Metabolic heterogeneity in breast cancer integrative clusters to screen metabolic vulnerabilities for diagnosis and treatment response
Journal Articles

Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death–Dependent Changes in Glycolysis

Richard L. Hesketh, Jiazheng Wang, Alan J. Wright, David Y. Lewis, Alice E. Denton, Richard Grenfell, Jodi L. Miller, Robert Bielik, Marcel Gehrung, Maria Fala, Susana Ros, Bangwen Xie, De-en Hu, Kevin M. Brindle
Journal: Cancer Research
Cancer Res (2019) 79 (14): 3557–3569.
https://doi.org/10.1158/0008-5472.CAN-19-0182
Published: 15 July 2019
View article titled, Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death–Dependent Changes in Glycolysis
Open the PDF for Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death–Dependent Changes in Glycolysis in another window
Includes: Supplementary data
Journal Articles

Metabolic Imaging Detects Low Levels of Glycolytic Activity That Vary with Levels of c-Myc Expression in Patient-Derived Xenograft Models of Glioblastoma

Richard Mair, Alan J. Wright, Susana Ros, De-en Hu, Tom Booth, Felix Kreis, Jyotsna Rao, Colin Watts, Kevin M. Brindle
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (18): 5408–5418.
https://doi.org/10.1158/0008-5472.CAN-18-0759
Published: 14 September 2018
View article titled, Metabolic Imaging Detects Low Levels of Glycolytic Activity That Vary with Levels of c-Myc Expression in Patient-Derived Xenograft Models of Glioblastoma
Open the PDF for Metabolic Imaging Detects Low Levels of Glycolytic Activity That Vary with Levels of c-Myc Expression in Patient-Derived Xenograft Models of Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract 2853: Imaging tumor metabolism to guide treatment of breast cancer with drugs targeted at PI3K alpha

Susana Ros, Paula D'Santos, De-en Hu, Ankita S. Batra, Alan J. Wright, Elizabeth Mannion, Alejandra Bruna, Carlos Caldas, Kevin M. Brindle
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2853.
https://doi.org/10.1158/1538-7445.AM2017-2853
Published: 01 July 2017
View article titled, Abstract 2853: Imaging tumor metabolism to guide treatment of breast cancer with drugs targeted at PI3K alpha